Alceus Biosciences Ltd
Manufacture of flat glass · London
ActiveUnited KingdomIncorporated 2024Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2025-10-31
IXBRL · 64 source facts · 4 selected values
Not assessedlegacy record
Accounts to 2025-10-31
IXBRL · 64 source facts · 4 selected values
Not assessed
legacy record
- Reporting period
- 2024-10-16 to 2025-10-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 22
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2025-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod223_4252_16021269_20251031
- Source archive
- Accounts_Bulk_Data-2026-06-30.zip
Accounts to 2025-10-31
IXBRL · 64 source facts · 4 selected values
Validation findingsXBRL valid
Accounts to 2025-10-31
IXBRL · 64 source facts · 4 selected values
Validation findings
XBRL valid
- Reporting period
- 2024-10-16 to 2025-10-31
- Extraction status
- complete
- Numeric facts
- 22
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2025-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2606_16021269_20251031
- Source archive
- Accounts_Monthly_Data-June2026.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Registered details
16021269- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 2024-10-16
- Jurisdiction
- —
- Registered office
- KRESTON REEVES LLP, 2ND FLOOR 168 SHOREDITCH HIGH STREET, LONDON, E1 6RA, ENGLAND
Classification
1 SIC codes23110
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
1 matched grantsDevelopment of cell-encoded therapeutics for advanced solid cancersLead
Innovate UK · Fast Start Response · 2025-11-01 – 2026-04-30
£47,398
awarded